 |
11 Diseases |  |
0 Trials |
|
0 Trials |  |
9 News |  |
- | Journal: Immunotherapy in indolent Non-Hodgkin's Lymphoma. (Pubmed Central) - Jun 8, 2022
Other agents include MAB targeting T-Cells like mogamulizumab, Denileukin Diftitox and BiTEs or bispecific T cell engagers like Mosunetuzumab, Glofitamab, and Epcoritamab...Another important aspect in immunotherapy is the half-lives of the medication which is an important factor that can influence the evaluation of the response. The MAB treatment showed important benefit in the treatment of iNHL and it continuously shows how rapidly it can develop to provide optimum care and benefit to patients with iNHL.
- || Orencia (abatacept) / BMS
Review, Journal: CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease. (Pubmed Central) - Jun 22, 2021
Therapeutic-based antibody towards CD80 (galiximab) had never been investigated in MCD or any kidney-related disease; hence, the role of CD80 is still undetermined. A new therapeutic approach towards MCD is essential to provide broader effective treatment options besides the general immunosuppressive agents with gruesome adverse effects.
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Epratucyn (epratuzumab) / Gilead
Clinical, Journal: The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. (Pubmed Central) - Mar 4, 2020
For early POD, the 2-year survival was 80% vs 99% for nonearly POD, and the 5-year survival was 74% vs 90%, respectively. These findings suggest that the adverse survival of patients with early POD may be independent of initial treatment modality.
- doxorubicin hydrochloride / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Epratucyn (epratuzumab) / Immunomedics
Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_3993;
Additional follow-up is underway to determine if positive pts will eventually relapse. CONCLUSIONS These data are the first to demonstrate that a high proportion of FL pts in a prolonged clinical remission have undetectable DNA by sensitive next generation sequencing, without evidence of clinical progression, and are potentially cured of their disease.
- galiximab (IDEC 114) / Biogen, Rituxan (rituximab) / Roche
Trial completion, Metastases: Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 25, 2015
P2, N=62, Completed, Sponsor: Alliance for Clinical Trials in Oncology
CONCLUSIONS These data are the first to demonstrate that a high proportion of FL pts in a prolonged clinical remission have undetectable DNA by sensitive next generation sequencing, without evidence of clinical progression, and are potentially cured of their disease. Active, not recruiting --> Completed
- galiximab (IDEC 114) / Biogen
Trial completion: Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 5, 2015
P2, N=30, Completed, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | galiximab (IDEC 114) / Biogen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Combination therapy: Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=90, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed